RGC Stock Explained: Zero Revenue, $11.7M Loss & DOJ Investigation

Regencell Bioscience (NASDAQ: RGC) presents one of the market's most unusual valuation puzzles: extreme share-price volatility, no reported revenue, substantial operating losses, and a disclosed U.S. Department of Justice investigation into trading in its shares. In this investor-focused analysis, we examine Regencell's FY2026 financial results, cash position, research spending, valuation risks, potential short-squeeze dynamics, and the implications of its latest annual filing. We also explain what the DOJ investigation does—and does not—establish, and why an adverse opinion on internal control over financial reporting matters to investors. Topics covered Regencell's business model and traditional Chinese medicine research DOJ investigation: confirmed disclosures versus unproven allegations FY2026 net loss, R&D spending and cash position Why traditional valuation multiples offer limited help when revenue is zero Short squeezes, thin trading float and downside volatility Governance, internal controls, financing and dilution risks Bull, base and bear scenarios for RGC Primary sources SEC FY2026 Form 20-F: https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/ea0307551-20f_regencell.htm Yahoo Finance RGC quote and market data: https://finance.yahoo.com/quote/RGC/ The Wall Street Journal's reporting on RGC's valuation and volatility: https://www.wsj.com/finance/stocks/regencell-bioscience-holdings-stock-value-b1b859e3 Disclaimer: This video is for educational and informational purposes only and is not financial, investment, legal, or medical advice. It is not a recommendation to buy, sell, or short any security. Share prices and market capitalization change; historical figures are dated snapshots. A government investigation is not proof of wrongdoing. Regencell's research candidates should not be interpreted as approved or proven treatments for ADHD or autism. Conduct your own research and consult qualified professionals before making investment decisions. 👍 Like the video if it helped you understand the risks. 💬 Comment with your analysis of RGC's valuation. 🔔 Subscribe and turn on notifications for more evidence-based stock analysis. ↗️ Share this video with investors who need to understand speculative-stock risk. #Regencell #RGC #RGCStock #StockMarket #StockAnalysis #BiotechStocks #PennyStocks #ShortSqueeze #DOJInvestigation #StockVolatility #SpeculativeStocks #InvestorEducation #MarketAnalysis #RiskManagement #Nasdaq